Ask about this productRelated genes to: MRPS17 antibody
- Gene:
- MRPS17 NIH gene
- Name:
- mitochondrial ribosomal protein S17
- Previous symbol:
- -
- Synonyms:
- HSPC011, RPMS17, MRP-S17
- Chromosome:
- 7p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-02-28
- Date modifiied:
- 2016-10-05
Related products to: MRPS17 antibody
Related articles to: MRPS17 antibody
- Lung adenocarcinoma (LUAD), characterized by its complex molecular heterogeneity and resistance to both conventional and targeted therapies, poses significant therapeutic challenges. Therefore, the identification of novel molecular targets is crucial for enhancing therapeutic strategies and improving patient outcomes. This study investigates the role of mitochondrial ribosomal protein S17 (MRPS17) in the progression of LUAD, with a specific focus on its interaction with the PI3K-AKT-mTOR signaling pathway. We conducted functional assays to assess cell proliferation, migration, invasion, and apoptosis in MRPS17-manipulated LUAD cell lines. Further, we explored the epigenetic regulation by TET1 through methylation analysis and investigated the downstream effects on the PI3K-AKT-mTOR pathway using Western blotting and reporter assays. Analysis revealed that MRPS17 is upregulated in LUAD tissues and is associated with a poor prognosis. In cellular models, MRPS17 overexpression was shown to promote proliferation, migration, and invasion, whereas its knockdown induced apoptosis and diminished tumorigenic capabilities both in vitro and in vivo. Importantly, TET1 was identified as a crucial regulator of MRPS17, acting through the demethylation of its promoter to enhance MRPS17 expression and subsequently activate the PI3K-AKT-mTOR pathway. MRPS17 significantly contributes to LUAD progression by enhancing tumor aggressiveness through the PI3K-AKT-mTOR pathway. The TET1-mediated demethylation of MRPS17 introduces a novel epigenetic mechanism that could be leveraged for targeted therapeutic interventions. This study not only provides foundational insights into the molecular biology of LUAD but also highlights the potential of MRPS17 as a prognostic marker and therapeutic target. - Source: PubMed
Publication date: 2026/08/29
Zhou NanSong LeiWu YangWei YingZhang WenwenWang BingbingZhao YanbinWang Yan - Diabetic foot ulcer (DFU) is one of the most common and severe complications of diabetes, with vascular changes, neuropathy, and infections being the primary pathological mechanisms. Disulfidptosis, a recently identified form of programmed cell death, might be involved in the development of diabetic complications. This study aims to identify and validate potential disulfidptosis biomarkers associated with DFU through bioinformatics and machine learning analysis. - Source: PubMed
Publication date: 2025/10/08
Li JIeShi HongshuoCao Yemin - Chromosomal alterations are frequent events in lung cancer progression. Although gains and losses of chromosomal position have been reported, the association between copy number alteration and lung cancer patient survival has not been extensively investigated. In this study, we performed a meta-analysis of public cBioPortal datasets spanning 25 lung cancer studies to identify putative cancer driver genes with copy number alterations associated with overall patient survival. Ten copy-number altered genes enriched in deceased lung cancer patients were identified. Seven of these putative driver genes were located in the 7p11.2 chromosomal location, and two were in the 9p21.3 cytoband. Among these genes, the mitochondrial ribosomal protein S17 (MRPS17) amplification was significantly associated with a lower patient survival rate ( = 1.47e-7). To investigate the functional role of MRPS17, small interfering RNA-mediated knockdown was performed in two non-small cell lung cancer cell lines, A549 and NCI-H460. MRPS17 knockdown significantly reduced cell proliferation, migration, invasion, and anchorage-independent growth in both cell lines. Furthermore, knockdown of MRPS17 decreased the activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, suggesting its role in driving lung cancer progression through this critical oncogenic pathway. Our findings highlight MRPS17 as a potential cancer therapy target and a prognostic biomarker that may improve the survival rates of lung cancer patients. Future studies should explore its inhibition as a therapeutic strategy as well as elucidate its molecular mechanisms in cancer progression. - Source: PubMed
Lee Woo RinHa Kook Sun - Gastric cancer (GC) is a highly aggressive malignancy with a heterogeneous nature, which makes prognosis prediction and treatment determination difficult. Inflammation is now recognized as one of the hallmarks of cancer and plays an important role in the aetiology and continued growth of tumours. Inflammation also affects the prognosis of GC patients. Recent reports suggest that a number of inflammatory-related biomarkers are useful for predicting tumour prognosis. However, the importance of inflammatory-related biomarkers in predicting the prognosis of GC patients is still unclear. - Source: PubMed
Hu Jia-LiHuang Mei-JinHalina HalikeQiao KunWang Zhi-YuanLu Jia-JieYin Cheng-LiangGao Feng - Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors, with a slow onset, rapid progression, and frequent recurrence. Previous research has implicated mitochondrial ribosomal genes in the development, metastasis, and prognosis of various cancers. However, further research is necessary to establish a link between mitochondrial ribosomal protein (MRP) family expression and HCC diagnosis, prognosis, ferroptosis-related gene (FRG) expression, m6A modification-related gene expression, tumor immunity, and drug sensitivity. - Source: PubMed
Publication date: 2023/07/05
Zhao Jin-WeiZhao Wei-YiCui Xin-HuaXing LinShi Jia-ChengYu Lu